Categories: Wire Stories

Solasia Announces Launch of Darvias� in Japan

TOKYO–(BUSINESS WIRE)–Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter �Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).


Contacts

Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations

Tel: +81 3 5843 8046 (TOKYO)

info@solasia.co.jp

Alex

Recent Posts

Carta continues with global expansion in Australia to support the country’s local startup and investor ecosystem

The US-based private capital software platform sets up base in Sydney as part of Investment…

10 mins ago

Mastering exotic currency pairs: trading strategies with global broker Octa

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 14 November 2024 - Adding exotic currency…

55 mins ago

SIBUR to Offset Carbon Footprint of Russia’s COP29 Delegation

MOSCOW, RUSSIA - Media OutReach Newswire - 14 November 2024 - SIBUR plans to offset…

55 mins ago

St. George’s University Invites South Korean Students to Apply for January 2025 Intake

SEOUL, SOUTH KOREA - Media OutReach Newswire - 14 November 2024 - St. George’s University…

3 hours ago

Swiss Business Hub: Global Fintechs Thrive on Switzerland’s Tech-Neutral Approach to AI

SINGAPORE - Media OutReach Newswire - 14 November 2024 - In the rapidly evolving landscape…

11 hours ago

CGTN:G20 pushes for global cooperation to eradicate hunger and poverty

BEIJING, CHINA - Media OutReach Newswire - 13 November 2024 - The first-ever Global Alliance…

11 hours ago